Podchaser Logo
Home
Oncology Times Broadcast NewsEpisode from the podcastOncology Times Broadcast News
Next Episode
Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

Released Tuesday, 6th October 2009
Good episode? Give it some love!
Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

Tuesday, 6th October 2009
Good episode? Give it some love!
Rate Episode
About
InsightsPodchaser Pro
Reviews
Credits
Lists
Transcript

Oncology Times Broadcast News

Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

Show More
Rate
Get this podcast via API

From The Podcast

Oncology Times Broadcast News

In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals.The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992.Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features
Podchaser Logo

Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More